Non-Invasive Risk Score Predicts Clinical Events in Primary Sclerosing Cholangitis
The study involved 419 patients, aged 18–75, with noncirrhotic PSC, who were randomly assigned to receive either cilofexor or a placebo over 96 weeks.
Allergy & Immunology